Eyepoint Pharmaceuticals’ (EYPT) “Hold” Rating Reiterated at Laidlaw

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “hold” rating reissued by investment analysts at Laidlaw in a research note issued on Tuesday, Benzinga reports.

EYPT has been the subject of a number of other reports. TD Cowen cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their target price for the company from $20.00 to $4.00 in a report on Wednesday, September 2nd. Guggenheim cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday. Chardan Capital downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price objective for the company. in a research report on Tuesday, August 18th. Wall Street Zen upgraded Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Finally, Cantor Fitzgerald lowered Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eyepoint Pharmaceuticals has an average rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Stock Up 2.3%

Shares of Eyepoint Pharmaceuticals stock traded up $0.01 during trading hours on Tuesday, reaching $0.45. 30,958,341 shares of the stock traded hands, compared to its average volume of 3,191,551. Eyepoint Pharmaceuticals has a one year low of $0.40 and a one year high of $19.11. The firm has a market capitalization of $38.79 million, a price-to-earnings ratio of -0.12 and a beta of 1.67. The company has a 50 day moving average price of $4.77 and a 200 day moving average price of $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The business had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Sell-side analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV bought a new position in Eyepoint Pharmaceuticals in the 1st quarter worth $29,000. Integrated Wealth Concepts LLC bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $72,000. Pictet Asset Management Holding SA bought a new stake in Eyepoint Pharmaceuticals during the first quarter valued at about $141,000. Engineers Gate Manager LP bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $161,000. Finally, Janney Montgomery Scott LLC lifted its position in shares of Eyepoint Pharmaceuticals by 14.8% in the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after acquiring an additional 3,900 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada said upcoming data from EyePoint’s diabetic macular edema (DME) study could provide a catalyst after the Phase 3 LUCIA trial in wAMD missed its primary endpoint. RBC maintained a “sector perform” rating but lowered its price target to $1.00, implying substantial potential upside from current levels. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says
• Positive Sentiment: EyePoint is prioritizing its late-stage DURAVYU program in DME, a move intended to reduce spending and concentrate resources on the company’s remaining major clinical opportunity. EyePoint Announces Strategic Prioritization
• Positive Sentiment: Trading activity included unusually high call-option volume, with 7,885 calls purchased—about 69% above typical daily volume—suggesting some speculative traders are positioning for a recovery, although this is not a fundamental improvement.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.